Lanicemine is a low-trapping N-methyl-D-aspartate (NMDA) receptor antagonist investigated for its potential in treating severe and treatment-resistant major depressive disorder. As a novel agent designed… Read more
Lanicemine is a low-trapping N-methyl-D-aspartate (NMDA) receptor antagonist investigated for its potential in treating severe and treatment-resistant major depressive disorder. As a novel agent designed to modulate glutamatergic neurotransmission with reduced psychotomimetic side effects, this compound requires rigorous analytical characterization during development. This category provides essential reference standards, including racemic hydrochloride salts, specific enantiomers, and stable isotope labelled compounds such as deuterated variants. Pharmaceutical laboratories utilize these materials for impurity profiling, method validation, and precise quantification in complex biological matrices. By employing these high-quality standards, researchers can ensure the accuracy of their analytical testing and maintain strict quality control throughout the lifecycle of the drug, supporting the development of therapeutic protocols for major depressive disorder.